SCHEMBL3662151

SCHEMBL3662151

Nc1ccccc1NC(=O)c1ccc(OCCCNC(=O)c2oc3ccccc3c2COc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.57
KDM4E B2RXH2 4/20 0.57
L3MBTL1 Q9Y468 4/20 0.57
MAPT P10636 2/20 0.57
HTT P42858 2/20 0.57
TDP1 Q9NUW8 1/20 0.57
ALDH1A1 P00352 2/20 0.55
HDAC1 Q13547 9/20 0.54
HDAC2 Q92769 4/20 0.54
HDAC3 O15379 3/20 0.54
HDAC10 Q969S8 2/20 0.54
HDAC8 Q9BY41 2/20 0.54
HDAC6 Q9UBN7 2/20 0.54
HDAC4 P56524 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC11 Q96DB2 1/20 0.54
HDAC9 Q9UKV0 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54
NCOR2 Q9Y618 1/20 0.54
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3664209 0.97 LMNA (0.58) LMNAKDM4EL3MBTL1MAPTHTT
SCHEMBL3662727 0.92 HDAC2 (0.56) LMNAKDM4EL3MBTL1MAPTHTT
SCHEMBL3660294 0.90 HDAC1 (0.59) LMNAKDM4EL3MBTL1MAPTHTT
SCHEMBL3662813 0.88 HDAC1 (0.61) LMNAKDM4EL3MBTL1MAPTHTT
SCHEMBL3666145 0.87 HDAC1 (0.56) LMNAKDM4EL3MBTL1MAPTHTT
SCHEMBL3663339 0.87 HDAC1 (0.56) LMNAKDM4EL3MBTL1MAPTHTT
SCHEMBL3658010 0.86 HDAC2 (0.58) LMNAKDM4EL3MBTL1MAPTALDH1A1
SCHEMBL3663986 0.86 HDAC1 (0.59) LMNAKDM4EL3MBTL1MAPTHTT
SCHEMBL3664172 0.86 HDAC1 (0.55) LMNAKDM4EL3MBTL1MAPTHTT
SCHEMBL3664790 0.85 HDAC2 (0.57) LMNAKDM4EL3MBTL1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292320-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2010-11-18 US claimed
EP-2220066-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS Gilead Colorado, Inc. (US) 2010-08-25 EP claimed
WO-2009079391-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2009-06-25 WO claimed
US-20100292320-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2010-11-18 US disclosed
EP-2220066-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS Gilead Colorado, Inc. (US) 2010-08-25 EP disclosed
WO-2009079391-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292320-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC7, HDAC5 LMNA 2401/4885KDM4E 66/4885L3MBTL1 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.